 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Pharmacokinetic data | |
| Metabolism | Renal[1] |
| Eliminationhalf-life | ~32 hours[1] |
| Excretion | Urine, feces[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H15ClN2O |
| Molar mass | 298.77 g·mol−1 |
| 3D model (JSmol) | |
| |
Ciclazindol (WY-23409) is anantidepressant andanorectic[2]drug of thetetracyclic[citation needed]chemical class that was developed in the mid to late 1970s, but was never marketed.[3][4] It acts as anorepinephrine reuptake inhibitor, and to a lesser extent as adopamine reuptake inhibitor.[3][5] Ciclazindol has no effects on theSERT,5-HT receptors,mACh receptors, orα-adrenergic receptors, and has only weak affinity for theH1 receptor.[5][6][7] As suggested by itslocal anesthetic properties,[6] ciclazindol may also inhibitsodium channels. It is known to blockpotassium channels as well.[8][9]
The dosage in human volunteers is stated to be 25 mg daily.[1] However, doses of up to 200 mg have also been reported.[2] This is surprising since the dosage of mazindol is only 2-4 mg per day.
Ciclazindol is reported to have an IC50 of 1.3 nM for thedopamine transporter (cmp 23).[10]
